EXHIBIT 99.1
HepaLife™ Enters Into New Cooperative Research
and Development Agreement with U.S. Government Agency
Boston, MA – November 27, 2007 -
HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625)
today announced that the Company has entered into a new Cooperative
Research and Development Agreement (CRADA) with the U.S. Department
of Agriculture, Agricultural Research Service (USDA, ARS) for
further optimization of HepaLife’s PICM-19 liver stem cell
line for application in the first-of-its-kind bioartificial liver
device.
Incorporating the PICM-19 cell line, HepaLife
is developing the first-of-its-kind bioartificial liver. HepaLife's
bioartificial liver, currently under development, is designed to
operate outside the patient's body. The bioartificial liver is
envisioned to mimic important functions of the human liver by
circulating the patient's blood inside the device, where it is
exposed to HepaLife's PICM-19 liver stem cells, thus processing the
patient's blood-plasma by removing toxins, enhancing metabolic
function, and ultimately, imitating the liver's natural
function.
“The execution of our new CRADA and the
announcement of our exclusive worldwide PICM-19 license agreement
with the USDA earlier this month, together mark important
objectives for HepaLife and for the development of our
bioartificial liver device,” stated Mr. Frank Menzler,
President and CEO of HepaLife. “We continue to achieve the
goals set in our business plan, both from a corporate and
scientific perspective, and are moving closer to initial in-vivo
trials.”
Intended for the treatment of liver failure,
the HepaLife™ Bioartificial Liver device consists of three
basic components: (1) a plasma filter, separating the
patient’s blood into blood plasma and blood cells; (2) the
bioreactor, a unit filled with PICM-19 cells which biologically
mimic the liver’s function; and (3), the HepaDrive™, a
perfusion system for pumping the patient's plasma through the
bioreactor while controlling gas supply and temperature for best
possible performance of the cells.
ABOUT HEPALIFE TECHNOLOGIES, INC.
HepaLife Technologies, Inc. (OTCBB: HPLF -
News; FWB: HL1) (WKN: 500625) is a developer of cell-based medical
technologies addressing prevalent human health concerns.
Current cell-based technologies under
development by HepaLife include 1) the first-of-its-kind artificial
liver device, 2) proprietary in-vitro toxicology and pre-clinical
drug testing platforms, and 3) novel cell-culture based vaccine
production methods for the manufacture of vaccines against H5N1
avian influenza and other viruses.
For additional information, please visit
www.hepalife.com .
To receive future press releases via email,
please visit:
http://www.hepalife.com/investor_alerts.php
To view the full HTML
text of this release, plea
